Back to Search
Start Over
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed.
- Source :
- Expert Review of Clinical Pharmacology; Sep2023, Vol. 16 Issue 9, p791-798, 8p
- Publication Year :
- 2023
-
Abstract
- Congenital anomalies of the kidney and urinary tract (CAKUT) can be associated with proteinuria, possibly leading to a decline in kidney function. The aim of this review is to evaluate evidence on the efficacy of renin-angiotensin-aldosterone system inhibitors (RAASi) in children affected by CAKUT with proteinuria or chronic kidney disease (CKD). We conducted a bibliographic search between 1 December 2022 and 20 February 2023, including randomized controlled trials, case-control studies, observational studies, meta-analyses, and systematic reviews dealing with the efficacy of RAASi in reducing proteinuria and slowing the decline of kidney function in children. RAASi are effective in reducing proteinuria and slowing CKD progression in many renal conditions; however, the efficacy of these drugs in patients affected by CAKUT with proteinuria is still unknown. While waiting for more evidence, when facing a child with CAKUT with isolated proteinuria or with proteinuria and CKD, a 6–12-month trial with RAASi with gradual increase to the maximal tolerated dose should be considered. If no improvement of proteinuria is obtained, the RAASi should be discontinued. [ABSTRACT FROM AUTHOR]
- Subjects :
- URINARY organs
CONGENITAL disorders
PROTEINURIA
RENIN
HUMAN abnormalities
NEPRILYSIN
Subjects
Details
- Language :
- English
- ISSN :
- 17512433
- Volume :
- 16
- Issue :
- 9
- Database :
- Complementary Index
- Journal :
- Expert Review of Clinical Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 171107252
- Full Text :
- https://doi.org/10.1080/17512433.2023.2247985